Compare Adaptive Biotechnologies Corp (ADPT) vs KraneShares Hang Seng TECH Index ETF (KTEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs KraneShares Hang Seng TECH Index ETF — how do they compare? Adaptive Biotechnologies Corp trades at $25.98 (market cap $4.05B), while KraneShares Hang Seng TECH Index ETF trades at $13.5. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, KraneShares Hang Seng TECH Index ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | KTEC | |
|---|---|---|
Market Cap | $4.05B | — |
Sector | Health | Sector/Thematic |
52-Week High | $25.45 | $19.51 |
52-Week Low | $12.15 | $12.00 |
Enterprise Value | $4.12B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.93, up 5.64% in 24 hours and near its 52-week high. The stock shows bullish technical momentum with improving fundamentals as revenue grew 55% year-over-year to $277M in 2025 while net losses narrowed significantly from -$159M to -$59M. The company's strategic shift to focus on its profitable MRD diagnostics business through a planned separation of Immune Medicine operations has driven investor optimism.
Outlook remains cautiously optimistic as ADPT transitions to a pure-play MRD company with strong gross margins exceeding 75%. While analyst consensus favors Buy ratings (65%), persistent net losses and high valuation multiples (P/S 12.6x, P/B 27.8x) present risks. The $25.50 price target suggests limited upside from current levels amid execution risks.
KTEC trades at $13.78, up 1.47% today, with a bullish technical signal driven by moving averages. Support and resistance cluster at $14, indicating a critical price zone. Financial ratios are unavailable, limiting fundamental clarity. Recent news highlights China's AI competition as a potential catalyst for tech ETFs like KTEC.
The stock's outlook hinges on AI sector momentum, but risks include reliance on thematic trends and lack of disclosed financials. Upside depends on broader tech ETF inflows, while volatility from geopolitical or market shifts poses a near-term challenge.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About KraneShares Hang Seng TECH Index ETF
KTEC tracks the Hang Seng TECH Index, providing targeted exposure to the 30 largest technology companies listed on the Hong Kong Stock Exchange. It focuses on innovative, internet-based businesses across sectors like e-commerce, fintech, cloud computing, and digital technology.
Read more on KTEC →
